Sep 15, 2025 · By 2030, these top-tier CDMOs are expected to capture a growing share of the biologics market, potentially exceeding 55%, as quality, scale, and reliability become critical …

Aug 28, 2024 · Here is a look at some of the top players dominating the global CDMO market today. Basel, Switzerland-based Lonza, reporting sales of CHF 6.7 billion in 2023, is one of the …

To help understand and highlight their development journey, we have made this special study that focuses on the Top 50 contract development and manufacturing organizations (CDMOs) in the …

WuXi Biologics's main competitors include Evotec, Catalent, Lonza, Samsung Biologics and Fujifilm Diosynth Biotechnologies. Compare WuXi Biologics to its competitors by revenue, …

Jul 22, 2024 · Explore CDMO trends post WuXi's US exit and discover who is poised to lead the industry forward.

Jul 11, 2024 · Discover the evolving CDMO landscape post-WuXi AppTec, with a growing influence of Indian CDMOs under the BIOSECURE Act.

Dec 20, 2024 · Below are 5 CDMOs who are poised to make the biggest impact on biopharma in 2025: 1. Catalent. With its $16 billion acquisition by Novo Holdings now complete, Catalent is …

Jul 10, 2025 · Boehringer Ingelheim Group, Wuxi Biologics (Cayman) Inc., Samsung Biologics, Lonza Group Ltd and Fujifilm Diosynth Biotechnologies USA Inc. are the major companies …

Explore WuXi Biologics's alternatives and competitors.

The biopharmaceutical contract manufacturing market is highly consolidated, dominated by five major players: Lonza (Switzerland), WuXi Biologics (China), Thermo Fisher Scientific Inc. (US), …